...
search icon
espr-img

Esperion Therapeutics Inc, Common Stock

ESPR

NMQ

$1.82

-$0.03

(-1.62%)

1D
Industry: Biotechnology Sector: Health Care

Analyst Forecast

Price Chart

Key Metrics

Market Cap info-icon
This is a company’s total value as determined by the stock market. It is calculated by multiplying the total number of a company's outstanding shares by the current market price of one share.
$344.82M
P/E Ratio info-icon
This is the ratio of a security’s current share price to its earnings per share. This ratio determines the relative value of a company’s share.
0
Volume info-icon
This is the total number of shares traded during the most recent trading day.
1.95M
Avg Volume info-icon
This is the average number of shares traded during the most recent 30 days.
0
Dividend Yield info-icon
This ratio shows how much income you earn in dividend payouts per year for every dollar invested in the stock (or the stock’s annual dividend payment expressed as a percentage of its current price).
0.00%
Beta info-icon
This measures the expected move in a stock’s price relative to movements in the overall market. The market, such as the S&P 500 Index, has a beta of 1.0. If a stock has a Beta greater (or lower) than 1.0, it suggests that the stock is more (or less) volatile than the broader market.
1.01
52-week Range info-icon
This shows the range of the stock’s price between the 52-week high (the highest price of the stock for the past 52 weeks) and the 52-week low (the lowest price of the stock for the past 52 weeks).
$1.58 L
$3.94 H
$1.82

About Esperion Therapeutics Inc, Common Stock

Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C. The company's products also include NILEMDO, an ATP Citrate Lyase (ACL) inhibitor that lowers LDL-C and cardiovascular risk by reducing cholesterol biosynthesis and up-regulating the LDL receptors; and NUSTENDI, a bempedoic acid and ezetimibe tablet to treat elevated LDL-C. The company has license and collaboration agreements with Daiichi Sankyo Co. Ltd to; Otsuka Pharmaceutical Co., Ltd; and Daiichi Sankyo Europe GmbH. Esperion Therapeutics, Inc. was incorporated in 2008 and is headquartered in Ann Arbor, Michigan. more

Industry: BiotechnologySector: Health Care

Returns

Time FrameESPRSectorS&P500
1-Week Return-2.15%1.67%0.11%
1-Month Return-15.35%3.31%1.23%
3-Month Return-26.32%2.21%2.87%
6-Month Return3.41%-4.82%8.93%
1-Year Return-30.27%1.22%22.83%
3-Year Return-58.26%15.75%42.13%
5-Year Return-97.05%42.34%83.14%
10-Year Return-97.16%103.03%189.73%

Financials

Dec '19Dec '20Dec '21Dec '22Dec '235YR TREND
Total Revenue148.36M227.55M78.45M75.47M116.33M[{"date":"2019-12-31","value":65.2,"profit":true},{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":34.48,"profit":true},{"date":"2022-12-31","value":33.17,"profit":true},{"date":"2023-12-31","value":51.13,"profit":true}]
Cost of Revenue175.61M2.39M14.22M26.97M43.27M[{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":1.36,"profit":true},{"date":"2021-12-31","value":8.1,"profit":true},{"date":"2022-12-31","value":15.36,"profit":true},{"date":"2023-12-31","value":24.64,"profit":true}]
Gross Profit(27.25M)225.16M64.23M48.51M73.07M[{"date":"2019-12-31","value":-12.1,"profit":false},{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":28.53,"profit":true},{"date":"2022-12-31","value":21.54,"profit":true},{"date":"2023-12-31","value":32.45,"profit":true}]
Gross Margin(18.36%)98.95%81.88%64.27%62.81%[{"date":"2019-12-31","value":-18.56,"profit":false},{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":82.75,"profit":true},{"date":"2022-12-31","value":64.95,"profit":true},{"date":"2023-12-31","value":63.48,"profit":true}]
Operating Expenses241.47M346.55M290.96M228.01M228.63M[{"date":"2019-12-31","value":69.68,"profit":true},{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":83.96,"profit":true},{"date":"2022-12-31","value":65.79,"profit":true},{"date":"2023-12-31","value":65.97,"profit":true}]
Operating Income(93.10M)(121.40M)(226.73M)(179.50M)(155.56M)[{"date":"2019-12-31","value":-9310100000,"profit":false},{"date":"2020-12-31","value":-12139600000,"profit":false},{"date":"2021-12-31","value":-22673000000,"profit":false},{"date":"2022-12-31","value":-17950100000,"profit":false},{"date":"2023-12-31","value":-15556300000,"profit":false}]
Total Non-Operating Income/Expense(12.18M)(44.83M)(88.73M)(110.97M)(111.93M)[{"date":"2019-12-31","value":-1218400000,"profit":false},{"date":"2020-12-31","value":-4482500000,"profit":false},{"date":"2021-12-31","value":-8873100000,"profit":false},{"date":"2022-12-31","value":-11096800000,"profit":false},{"date":"2023-12-31","value":-11193300000,"profit":false}]
Pre-Tax Income(97.17M)(143.55M)(269.11M)(233.66M)(209.25M)[{"date":"2019-12-31","value":-9716500000,"profit":false},{"date":"2020-12-31","value":-14355100000,"profit":false},{"date":"2021-12-31","value":-26910800000,"profit":false},{"date":"2022-12-31","value":-23365900000,"profit":false},{"date":"2023-12-31","value":-20924800000,"profit":false}]
Income Taxes11.86M22.64M49.72M54.16M(3.90K)[{"date":"2019-12-31","value":21.89,"profit":true},{"date":"2020-12-31","value":41.8,"profit":true},{"date":"2021-12-31","value":91.8,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":-0.01,"profit":false}]
Income After Taxes(109.02M)(166.19M)(318.82M)(287.82M)(209.24M)[{"date":"2019-12-31","value":-10902200000,"profit":false},{"date":"2020-12-31","value":-16618900000,"profit":false},{"date":"2021-12-31","value":-31882400000,"profit":false},{"date":"2022-12-31","value":-28781700000,"profit":false},{"date":"2023-12-31","value":-20924410500,"profit":false}]
Income From Continuous Operations(97.17M)(143.55M)(269.11M)(233.66M)(208.39M)[{"date":"2019-12-31","value":-9716500000,"profit":false},{"date":"2020-12-31","value":-14355100000,"profit":false},{"date":"2021-12-31","value":-26910800000,"profit":false},{"date":"2022-12-31","value":-23365900000,"profit":false},{"date":"2023-12-31","value":-20839100000,"profit":false}]
Income From Discontinued Operations-----[{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}]
Net Income(109.02M)(166.19M)(318.82M)(287.82M)(209.25M)[{"date":"2019-12-31","value":-10902200000,"profit":false},{"date":"2020-12-31","value":-16618900000,"profit":false},{"date":"2021-12-31","value":-31882400000,"profit":false},{"date":"2022-12-31","value":-28781700000,"profit":false},{"date":"2023-12-31","value":-20924800000,"profit":false}]
EPS (Diluted)(3.72)(5.48)(9.56)(3.55)(2.12)[{"date":"2019-12-31","value":-372,"profit":false},{"date":"2020-12-31","value":-548,"profit":false},{"date":"2021-12-31","value":-956,"profit":false},{"date":"2022-12-31","value":-355,"profit":false},{"date":"2023-12-31","value":-212,"profit":false}]

Ratios

Liquidity

These ratios help you determine the liquidity of the company. Higher is better.

ESPR
Cash Ratio 0.87
Current Ratio 1.85
Quick Ratio 1.37

Asset Efficiency

These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.

ESPR
ROA (LTM) 3.84%
ROE (LTM) -260.79%

Liabilities

These ratios help you understand the company's liabilities, gauging the riskiness of the investment.

ESPR
Debt Ratio Lower is generally better. Negative is bad. 2.18
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. -1.18

Valuation

These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.

ESPR
Trailing PE NM
Forward PE 1.34
P/S (TTM) 1.23
P/B 98.42
Price/FCF NM
EV/R 1.69
EV/Ebitda NM
PEG NM

FAQs

What is Esperion Therapeutics Inc share price today?

Esperion Therapeutics Inc (ESPR) share price today is $1.82

Can Indians buy Esperion Therapeutics Inc shares?

Yes, Indians can buy shares of Esperion Therapeutics Inc (ESPR) on Vested. To buy Esperion Therapeutics Inc from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in ESPR stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.

Can Fractional shares of Esperion Therapeutics Inc be purchased?

Yes, you can purchase fractional shares of Esperion Therapeutics Inc (ESPR) via the Vested app. You can start investing in Esperion Therapeutics Inc (ESPR) with a minimum investment of $1.

How to invest in Esperion Therapeutics Inc shares from India?

You can invest in shares of Esperion Therapeutics Inc (ESPR) via Vested in three simple steps:

  • Click on Sign Up or Invest in ESPR stock at the top of this page
  • Breeze through our fully digital and secure KYC process and open your US Brokerage account in a few minutes
  • Transfer USD funds to your US Brokerage account and start investing in Esperion Therapeutics Inc shares
What is Esperion Therapeutics Inc 52-week high and low stock price?

The 52-week high price of Esperion Therapeutics Inc (ESPR) is $3.94. The 52-week low price of Esperion Therapeutics Inc (ESPR) is $1.58.

What is Esperion Therapeutics Inc price-to-book (P/B) ratio?

The price-to-book (P/B) ratio of Esperion Therapeutics Inc (ESPR) is 98.42

What is the Market Cap of Esperion Therapeutics Inc?

The market capitalization of Esperion Therapeutics Inc (ESPR) is $344.82M

What is Esperion Therapeutics Inc’s stock symbol?

The stock symbol (or ticker) of Esperion Therapeutics Inc is ESPR

Signup to access all features and start your US investing journey!

  • Open your account in minutes
  • Take your portfolio global, starting at just $1
Get started

Add ticker to compare

Scroll to Top